InSphero AG Press Releases

• Published on November 25, 2024 - 15:17 GMT

  

  InSphero and FDA’s NCTR Publish the Largest Benchmarking Study on Early-stage Liver Toxicity Using 3D Liver Microtissues

  InSphero’s 3D liver microtissues predicted liver toxicity with 80% accuracy in a study with 152 drugs, advancing human-based safety testing. ZüRICH, SWITZERLAND, November 25, 2024 /⁨EINPresswire.com⁩/ -- InSphero, the global leader in 3D cell culture …

  Distribution channels: Education, Healthcare & Pharmaceuticals Industry ...
• Published on November 19, 2024 - 07:00 GMT

  InSphero Awarded Major EU Grant to Address Diversity in 3D In Vitro Testing

  InSphero leads in the Chips JU UNLOOC Project to advance 3D cell culture and improve drug testing. SCHLIEREN, SWITZERLAND, November 19, 2024 /⁨EINPresswire.com⁩/ -- InSphero, the global leader in scalable and reliable 3D in vitro cell culture solutions …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
• Published on November 4, 2024 - 19:19 GMT

  InSphero Partners with Chayon to Bring Advanced 3D In Vitro Technologies to South Korean Researchers

  InSphero has partnered with Seoul-based Chayon to provide 3D in vitro solutions for drug development to South Korean researchers. SCHLIEREN, SWITZERLAND, November 4, 2024 /⁨EINPresswire.com⁩/ -- InSphero, the pioneer in 3D cell culture and organ-on-chip …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
• Published on August 19, 2024 - 15:33 GMT

  

  InSphero, Breakthrough T1D and Université libre de Bruxelles Collaborate to Find New Cures for Type 1 Diabetes

  InSphero, Breakthrough T1D, and ULB partner to discover novel T1D treatments, aiming to protect and preserve vital insulin-producing pancreatic beta cells. SCHLIEREN, ZURICH, SWITZERLAND, August 19, 2024 /⁨EINPresswire.com⁩/ -- InSphero, a leading …

  Distribution channels: Education, Healthcare & Pharmaceuticals Industry ...
• Published on May 16, 2024 - 14:34 GMT

  InSphero Secures Exclusive Commercialization Partnership with Genome Biologics for 3D Cardiac Organoid Platform

  InSphero AG is pleased to announce its exclusive commercialization of TrueCardium® Cardiac Organoid Platform in partnership with Genome Biologics. SCHLIEREN, ZURICH, SWITZERLAND, May 16, 2024 /⁨EINPresswire.com⁩/ -- In a significant expansion of its …

  Distribution channels: Banking, Finance & Investment Industry, Building & Construction Industry ...
• Published on March 15, 2024 - 16:50 GMT

  

  InSphero and PharmaNest Unveil a Promising Tool for MASH Drug Discovery in a Breakthrough Study

  InSphero published a groundbreaking peer-reviewed paper in Nature's Scientific Reports, challenging the limitations of in vitro models in MASH Drug Discovery. SCHLIEREN, ZURICH, SWITZERLAND, March 15, 2024 /⁨EINPresswire.com⁩/ -- InSphero's Liver …

  Distribution channels: Banking, Finance & Investment Industry, Building & Construction Industry ...
• Published on November 17, 2023 - 14:01 GMT

  InSphero to Revolutionize Oncology Research Through Advanced 3D Cell-Based Assays with ATCC

  InSphero AG and ATCC will work together to introduce new paradigms in the rapidly evolving field of 3D cell-based oncology research. SCHLIEREN, ZURICH, SWITZERLAND, November 17, 2023 /⁨EINPresswire.com⁩/ -- InSphero AG, the global leader in 3D cell …

  Distribution channels: Banking, Finance & Investment Industry, Building & Construction Industry ...
• Published on October 18, 2023 - 11:59 GMT

  InSphero Launches New Website Showcasing “The Model of Excellence™” Empowering Breakthroughs in 3D In Vitro Therapies

  InSphero AG, a global leader in 3D in vitro technologies, is thrilled to announce the launch of its brand-new website. SCHLIEREN, ZURICH, SWITZERLAND, October 18, 2023 /⁨EINPresswire.com⁩/ -- InSphero AG, a global leader in 3D in vitro technologies, is …

  Distribution channels: Banking, Finance & Investment Industry, Building & Construction Industry ...
• Published on August 2, 2023 - 11:50 GMT

  InSphero AG and Cosmo Bio Co., Ltd Enter into Partnership to Distribute InSphero’s Innovative Product Portfolio in Japan

  InSphero AG and Cosmo Bio Co., Ltd Enter into Strategic Partnership to Distribute InSphero’s Innovative Product Portfolio in Japan ZURICH, ZURICH, SWITZERLAND, August 2, 2023 /⁨EINPresswire.com⁩/ -- InSphero AG and Cosmo Bio Co., Ltd. are announcing a …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
• Published on July 25, 2023 - 15:29 GMT

  

  The Physicians Committee and InSphero Launch Award Program to Accelerate Adoption of Human In Vitro Models

  SCHLIEREN, SWITZERLAND, July 25, 2023 /⁨EINPresswire.com⁩/ -- The Physicians Committee for Responsible Medicine and InSphero AG, two organizations at the forefront of innovative, human-centric life-science research, have announced the launch of a joint …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
• Published on March 31, 2023 - 09:00 GMT

  

  InSphero Accelerates Launch of Cryopreserved 3D Microtissue Platform with new Investment Round Led by ZEISS Ventures

  Allows streamlining the R&D process for researchers desiring deeper insights in human biology by storable, ready-to-use 3D models ZURICH, SWITZERLAND, March 31, 2023 /⁨EINPresswire.com⁩/ -- Swiss-based InSphero, the global market leader in 3D spheroid …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
• Published on March 13, 2023 - 07:45 GMT

  

  Vrije Universiteit Brussel (VUB) and InSphero Partner to Advance Drug Discovery for Non-Alcoholic Steatohepatitis

  InSphero, leader in enabling pharma researchers to use predictive, human 3D cell-based disease models expands its NASH portfolio in collaboration with VUB SCHLIEREN, SWITZERLAND, March 13, 2023 /⁨EINPresswire.com⁩/ -- Vrije Universiteit Brussel (VUB) …

  Distribution channels: Banking, Finance & Investment Industry, Chemical Industry ...
• Published on February 13, 2019 - 13:00 GMT

  

  InSphero Appoints Distinguished Pharma Industry Executive Prof. Armin Wolf as Chief Scientific Officer

  With 30 years of cumulative experience at Novartis and Janssen, Prof. Wolf strengthens InSphero leadership team and augments 3D model and organ-on-a-chip R&D. SCHLIEREN, SWITZERLAND, February 13, 2019 /⁨EINPresswire.com⁩/ -- InSphero AG today …

  Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...
• Published on February 1, 2019 - 13:00 GMT

  

  InSphero Organ-on-a-Chip Solutions Featured in SLAS Technology

  Early proof-of-concept studies demonstrate versatility of scalable microfluidic platform for 3D microtissue-based, multi-organ models SCHLIEREN, ZURICH, SWITZERLAND, February 1, 2019 /⁨EINPresswire.com⁩/ -- The February 2019 issue of the scientific …

  Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...
• Published on January 24, 2019 - 13:00 GMT

  

  Registration Open for 2019 New Frontiers in 3D Conference

  Exclusive one-day scientific meeting to discuss practical applications of innovative 3D-cell and organ-on-a-chip technologies to be held April 25, 2019 at MIT SCHLIEREN, SWITZERLAND, January 24, 2019 /⁨EINPresswire.com⁩/ -- Registration and abstract …

  Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...